VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01655589

Enrollment

Registered

2012-08-02

Start date

2008-01-31

Completion date

Unknown

Last updated

2012-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Brief summary

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of neovascular age-related macular degeneration * Visual acuity better than 20/400 * Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months * Follow-up period of at least six months

Exclusion criteria

* Choroidal neovascularization secondary to any other cause than age-related macular degeneration * Eyes with polypoidal choroidal vasculopathy * Eyes previously submitted to posterior vitrectomy * Other diseases that could affect visual acuity

Countries

Brazil

Outcome results